Donate Now
Home | News | Events | Press | Contact  

About UseNewsletterMessage BoardsAction CenterAdvocateWalk to End Alzheimer’sShopDonate

Find your chapter:

search by state

In My Community
Helping You
Text Size controlsNormal font sizeMedium font sizeLarge font size


The Alzheimer’s Association - Rhode Island Chapter is here to help.

Support

Helpline
Care consultation
Support groups
Message boards

Education

Publications
Newsletter
Education programs
Professional training
Multilingual information

Resources

Safe Return®
Local resources and referrals
Clinical trials index

Helpline

The Alzheimer's Association Helpline operates 24 hours a day, seven days a week, in 140 languages. Our staff is highly trained and knowledgeable about all aspects of Alzheimer’s disease. Call us if you have questions about:

  • Alzheimer’s disease or memory loss, medications and treatment options, brain health and care options

  • How the Association can help you

  • Caregiving tips and respite care options

  • Services available in your community and referrals

You can also call us for emotional support –– as often as you need. We know that living with Alzheimer’s can be overwhelming at times. Remember, we are here for you –– all day, every day.

E-mail help

If you prefer, click contact us via email. We check the e-mail box daily during the workweek and will respond to your inquiry as soon as possible.

Care Consultation

Our professional staff is dedicated to helping people navigate through the difficult decisions and uncertainties people with Alzheimer’s and their families face at every stage of the disease. We can provide care consultation services to you by telephone, e-mail or in person. These include:

  • Assessment of needs

  • Assistance with planning and problem solving

  • Supportive listening

Contact us for more information:

Office: 401-421-0008
Toll Free: 1.800.272.3900

Long-Term Care Facilities

View our list ofLong-Term Care Facilities in Rhode Island with special care units including Assisted Living and Skilled Nursing facilities.



Support Groups

We offer a variety of support groups for all individuals living with Alzheimer’s disease. Groups are facilitated by trained volunteers. Many locations offer specialized groups for children, those with early-onset and early-stage Alzheimer’s, adult caregivers and others with specific needs.

Support group listing.

Early Stage Programs

The Early Stage Program is offered to people who have a diagnosis of early memory loss. It focuses on maintaining the quality of one's life as they learn to communicate with others on what it's like having memory loss so to maintain an active lifestyle. The program gives participants the opportunity to exercise, learn ways to manage the changes in memory from each other and group facilitators trained by the Alzheimer's Association RI Chapter.

Simultaneously, the program provides time for care partners to pursue their own interests.  The program offers valuable information/resources to families living with someone who has a diagnosis of memory loss in Rhode Island.

An interview with a staff person is required in order to determine whether the program meets the applicant's needs. Please contact Annie Murphy, Early Stage Program Coordinator at 401-421-0008 for further information.

The Early Stage Program schedule is below.
 

Warwick Library, Warwick RI   Tuesday, 9:30am - 11:30am 
St. Francis de Sales, No. Kingstown, RI Thursday, 10:00am - Noon 
East Side/Mt. Hope YMCA, Providence, RI   Wednesday, 11:00am - 1:00pm 
Woonsocket Library, Woonsocket, RI   Wednesday, 9:30am - 11:30am 
St. Lucy's Church, Middletown, RI   Tuesday, 9:30am - 11:30am

Click here to view the Early Stage Program brochure. 


Click here for information on our upcoming education series  for people living in the early stages of Alzheimer's and their care partners; Living with Alzheimer's for People with Alzheimer's and Living with Alzheimer's for Care Partners.  Both workshops will run simultaneously.  The diagnosis of Alzheimer's is life changing and leads to many questions for the person diagnosed and their care partners.  This educational series will help you better understand the disease and what you need to know now and for future plannning.


Message boards

The Alzheimer’s Association message boards and chat rooms provide an online community for persons with Alzheimer's, caregivers and care providers. Our message boards have thousands of registered members from around the United States and thousands more who refer to the stories and information that is available 24 hours a day.

Join the Alzheimer’s Association online community.

Publications

The Alzheimer’s Association offers dozens of fact sheets and brochures. Click here for a listing.

We also maintain a variety of educational materials (brochures, videos, audiotapes and books) on topics related to Alzheimer’s disease and related disorders. Our library books and videos are available to borrow, to learn more about our library, call us at 401-421-0008

Newsletter

Sign up for our newsletter by emailing your name and address to Camilla.Farrell@alz.org

Educational programs

We offer many educational programs each year that address the specific interests of the general public, individuals with the disease and their families.

Education program listing.

Professional training

We offer classroom and Web-based training for healthcare supervisors and direct care workers in assisted living and nursing homes. Many programs allow you to earn CEUs.

Professional training listings.

Multilingual information

Alzheimer’s disease and other disorders that cause dementia know no boundaries. Many individuals and families in ethnic and cultural minority groups are in need of solid information about Alzheimer’s disease and health resources.

Safe Return®

Alzheimer's Association Safe Return® is a nationwide identification, support and enrollment program that provides assistance when someone with Alzheimer's or a related dementia wanders and becomes lost. Assistance is available 24 hours a day, 365 days a year. If an enrollee is missing, one phone call immediately activates a community support network to help reunite the lost person with his or her caregiver.

We offer assistance to low income families for this service. Please contact us for more information.

Learn more about Safe Return.

Local resources and referrals

We maintain updated information on home care, adult day care, care coordination, assisted living, skilled nursing facilities, eldercare lawyers and transportation available in the community. Our staff and trained professionals can help assess whether a specific care provider meets the needs of an individual with Alzheimer’s.

For more information, please contact us:

By phone: 1.800.272.3900
By e-mail: Marge.Angilly@alz.org

Clinical trials index

BUTLER HOSPITAL (Memory and Aging Program)

Study name: A study of working memory and frontal white matter in the brains of persons with mild cognitive impairment or with normal memory

Description: This study involves no treatment. It consists of memory testing and a new type of MRI given on separate occasions. It examines the relationship between how people perform on tests of thinking abilities and the health of this part of the brain.

Eligibility:
Participants aged 55 or older who have mild memory problems or have no memory problems

Contact: Steven Correia, Ph.D. at 401-455-6403


Study name: An open label, 8-week clinical trial of the safety and efficacy of Escitalopram for the treatment of depression and anxiety in caregivers of persons with dementia

Description: This study is designed to help caregivers who may be feeling stressed, nervous or depressed; participants do not have to be diagnosed with a clinical depression.

Eligibility: Participants must: be between the ages of 18 and 90; have normal memory, be able to travel to study clinic; provide at least 20 hours/week of direct care and supervision to a person with dementia.

Contact: Gary Epstein-Lubow, MD at 401-455-6384 or at GEpsteinLubow@Butler.org


Study name: Caregiver Health Assessment survey conducted by Butler Hospital and Brown University.

Description: This study is designed to assess the feelings and thoughts caregivers may be experiencing through completion of a written questionnaire. Half of the participants will then be randomly selected to be part of a follow-up study.

Eligibility: Participants must be caregivers of persons who have been diagnosed with a memory problem or an anxiety or depressive disorder.

Contact: Gary Epstein-Lubow, M.D. or Ivan Miller, Ph.D. at 455-6384 or GEpsteinLubow@Butler.org


Study name: A study of apathy in Alzheimer’s disease (AD)

Description: This 8 week study is to determine if modafinil (a drug already approved for the treatment of other conditions) will reduce the symptoms of apathy in persons with mild to moderate AD.

Apathy, the most common behavioral symptom of AD, is a distinct syndrome that can be distinguished from depression; it is defined as a loss of motivation and has symptoms which may include blunted emotions, loss of interest in previously enjoyed activities, poor effort and reduced social engagement. Treatments for depression may not reduce symptoms of apathy.

Eligibility: Participants must be: diagnosed with mild to moderate AD; between the ages of 60 and 90; and experiencing symptoms of apathy.

Contact: Laura Frakey, Ph.D. at 401-455-6355


Study Name: A Phase III randomized, double-blind, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) (RSG XR) as adjunctive therapy in mild to moderate AD patients already being treated with donepezil (Aricept). This study is called REFLECT-2.

Description: This study runs for 54 weeks and is designed to test whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer’s disease (AD) when combined with the currently approved AD medication, Aricept (donepezil). RSG XR is a new approach to AD therapy by testing whether one’s genetic makeup affects the participant’s response to the study drug.

Eligibility: Participants must be 50-90 years old and diagnosed with mild to moderate AD; at least 6 months of ongoing donezepil therapy, and have a regular care partner that can accompany them to the 10 study visits.

Contact: Betty Blackham RN at Butler Hospital Memory and Aging Program at 401-455-6403 or by email to bblackham@butler.org.


RHODE ISLAND HOSPITAL (Alzheimer’s Disease and Memory Disorders Center)

Bapineuzumab clinical trial:This study will determine if intravenous administration of a specific antibody against beta amyloid can slow the progression of Alzheimer’s disease.
Elan Pharmaceuticals, Inc.
Contact Esther Oden at 444-7691.


RAGE (Receptor for Advanced Glycation End-products) inhibitor trial: This study will determine the safety and efficacy of PF-04494700 for the treatment of Alzheimer’s disease through a novel mechanism aimed against amyloid deposition in the brain.
Pfizer/ National Institutes of Health/NIA/ADCS.
Contact Esther Oden at 444-7691.


Intravenous Immunoglobulin (IVIG) clinical trial: This study will determine if intravenous administration of a mixture of antibodies, including those against beta amyloid, can slow the progression of Alzheimer’s disease.
National Institutes of Health/NIA/ADCS.
Contact Teresa Erbozkurt at 444-6922.


A study of the effect of cholinesterase inhibitors on driving related cognitive abilities.This study examines whether treatment of Alzheimer’s disease with cholinesterase inhibitor drugs may be beneficial to cognitive abilities needed for safe driving.
National Institutes of Health/NIA.
Contact Lori Daiello at 444-3337.


Efficacy of Quantitative EEG Neurocognitive Training in Early-Stage Alzheimer's Disease (NeuroFeedback). This study will assess the efficacy of NeuroFeedback Training to enhance cognitive performance in early Alzheimer’s disease.
The Alzheimer’s Association.
Contact Elena Festa-Martino, PhD at 863-9168.


Psychosocial telephone intervention for dementia caregivers. This study is to determine the efficacy of a telephone-based, psychosocial intervention to improve caregiver burden and depression in dementia caregivers.
National Institute of Health/NINR.
Contact Dr. Geoffrey Tremont at 444-4500.


Telephone Screening for Mild Cognitive Impairment (TeleMem) study:This study will develop a cost effective screening method to identify persons with mild cognitive impairment or very early stage Alzheimer’s disease using a set of test questions administered over the telephone.
Nation’s Carelink.
Contact Michael McQuiggan at 444-3673.


Naturalistic assessment of driving in cognitively impaired elders. This study will define the basis of driving impairment in Alzheimer’s disease and develop computerized test predictors of impaired road test performance and driving ability in the natural home environment.
National Institutes of Health/NIA.
Contact Lindsay Miller at 444-0789.


Validation of Imaging Evaluations in Individuals With Alzheimer's Disease and Healthy Subjects (VIEW-AD).This study is to evaluate multiple brain imaging markers for Alzheimer disease and identify SPECT compounds that most clearly distinguish Alzheimer's disease from healthy persons of similar age.
Institute for Neurodegenerative Disorders.
Contact Lindsay Miller at 444-0789.


Wellness Approaches for Mild Cognitive Impairment.This study will compare the potential utility of two separate wellness techniques (yoga and wellness seminars) to enhance cognition in people with mild cognitive impairment.
Contact Michael McQuiggan at 444-3673.

RHODE ISLAND MOOD & MEMORY RESEARCH INSTITUTE

Study Name: A Phase III randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of Namenda® in persons with moderate-to-severe Alzheimer's disease (AD)

Description: This is a 26-week study to evaluate Namenda® when used with a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®) for persons with moderate to severe AD.

Eligibility: Participants must be at least 50 years old; diagnosed with moderate to severe stage of AD; accompanied by a reliable caregiver who can provide information for the study; currently on a 3 month stable dose of a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®).

Contact: RIMMRI at 401-435-8950 or by e-mail to mmello@rimmri.com


Study Name: A Phase III randomized, double-blind , placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors (Aricept®, Exelon® or Razadyne®) on cognition and overall clinical response in APOE ε4-stratified persons with mild to moderate Alzheimer’s disease (AD) This study is called REFLECT-3.

Description: This study runs for 54 weeks and is designed to test an extended release tablet for the treatment of persons with mild to moderate AD who may or may not be taking a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®).

Eligibility: Participants must be at least 50 years old and diagnosed with mild to moderate AD; if on a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®) they must be on a 2 month stable dose. They must be accompanied by a reliable caregiver who has daily interaction with the study participant.

Contact: RIMMRI at 401-435-8950 or by e-mail to mmello@rimmri.com


Study Name: A Phase III multinational, randomized, double blind, placebo controlled study of the effect of daily treatment with MPC-7869 (Flurizan™) on measures of cognition, activities of daily living and general mental performance in persons with mild Alzheimer’s disease (AD)

Description: This study runs for 18 months and is designed to determine the effectiveness of this investigational medication in the treatment of individuals with mild AD.

Eligibility: Participants must be at least 55 years old, diagnosed with mild AD; may be on Namenda® with a 3-month stable dose or on an cholinesterase inhibitor (Aricept®, Exelon®, or Razadyne®) with a 6-month stable dose, accompanied by a reliable caregiver with at least 4 days per week interaction with the participant

Contact: RIMMRI at 401-435-8950 or by e-mail to mmello@rimmri.com


Study Name: A prospective, multi-center, single arm pilot study to evaluate the safety and tolerability of Exelon® Capsule with add on Namenda® HCI in persons with probable Alzheimer’s disease (AD).

(Mini-Mental Status Exam score must be between 10-20 points.)

Description: This study runs for 26 weeks and is designed to determine the effectiveness/safety of Exelon® and Namenda® as treatment for persons with AD. This is an open label study.

Eligibility: Participants must be: at least 50 years old, diagnosed with probable AD, receiving a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®) for less than 6 months, and accompanied by a caregiver with at least 3 full days of interaction with the participant and daily phone contact.

Contact: RIMMRI at 401-435-8950 or by e-mail to mmello@rimmri.com


Study Name: A Phase II double-blind, placebo-controlled study of the activity of AVE1625 at doses of 10 mg and 40 mg for 12 weeks in persons with mild to moderate Alzheimer's disease (AD).

Description: This is an 18 to 24 week safety study for persons diagnosed with mild to moderate AD.

Eligibility: Participants must be: at least 50 years of age, on stable dose of a cholinesterase inhibitor (Aricept®, Exelon® or Reminyl®) for at least 3 months and accompanied by a caregiver with at least daily interaction with the participant. Participant cannot be taking Namenda®.

Contact: RIMMRI at 401-435-8950 or by e-mail to mmello@rimmri.com


Study Name: A Phase III randomized, double-blind, placebo-controlled, multi-center study of the safety, tolerability and efficacy of 3 doses of Lecozotan (SRA-333) SR in persons with mild to moderate Alzheimer’s disease (AD) with donepezil (Aricept®) as active control

Description: This is a 3-month trial for participants diagnosed with mild to moderate AD with a follow-up open label component.

Eligibility: Participants must be: at least 50 years of age, currently not taking Namenda® or a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®) and accompanied by a caregiver who has at least daily visits with the participant.

Contact: RIMMRI at 401-435-8950 or by e-mail to mmello@rimmri.com


Study Name: A Phase III randomized, double-blind, placebo-controlled multicenter, study of the safety, tolerability and efficacy of 3 Doses of Lecozotan (SRA-333) SR in persons with mild to moderate Alzheimer’s disease (AD) treated with a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®).

Description: This is a 6 month trial for persons who are diagnosed with mild to moderate AD with a follow-up open label component.

Eligibility: Participants must be: at least 50 years of age: on a 3-month stable dose of a cholinesterase inhibitor (Aricept®, Exelon® or Razadyne®); and accompanied by a caregiver who has at least daily visits with the participant.

Contact: RIMMRI at 401-435-8950 or by e-mail to mmello@rimmri.com


     

    Alzheimer's Association

    Our vision is a world without Alzheimer's
    Formed in 1980, the Alzheimer's Association is the world's leading voluntary health organization in Alzheimer's care, support and research.